Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
|Articles|November 2, 2011
- Pharmaceutical Technology-11-02-2011
- Volume 35
- Issue 11
Pharmaceutical Technology, November 2011 Issue (PDF)
Click the title above to open the Pharmaceutical Technology November 2011 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 15 years ago
Growth for Small Pharmaalmost 15 years ago
Drug Shortages Create Crisis for Manufacturers, Regulatorsalmost 15 years ago
Using Simulation to Improve Drug-Delivery Effectivenessalmost 15 years ago
Easy on the Alcohol!almost 15 years ago
Catalyzing the Synthesisalmost 15 years ago
Super Fast Pharmaalmost 15 years ago
Global Healthcare on the Ground: Novartis Focuses on Treating Rare Diseasesalmost 15 years ago
Managing the Global Clinical-Trial Material Supply Chainalmost 15 years ago
In the Spotlight November 2011almost 15 years ago
Biosimilars' Technology NeedsAdvertisement
Related to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
5